Antimania drugs are psychotropic drugs that are used to treat mania. While the exact causes are many, the most common is bipolar disorder. Similar to these bipolar disorder drugs, antimanic drugs are effective in treating a wide variety of symptoms.
These drugs are majorly used for the treatment of acute mania include lithium, valproate & carbamazepine (antipsychotics), ziprasidone, aripiprazole & clozapine (atypical antipsychotics), and lorazepam (benzodiazepine).
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
Growing prevalence of bipolar disorder, globally is driving growth of the antimania drugs market. For instance, according to the World Health Organization (WHO) 2019 report, around 45 million people get affected by bipolar disorder globally.
Moreover, cost effectiveness of drugs for the treatment of bipolar disorder is another factor that is expected to drive the global antimania drugs market growth over the forecast period. For example, cost of olanzapine is US$ 153, while cost of lithium is US$ 16 per month.
Additionally, growing number of clinical trials of drug for the treatment of bipolar depression, is expected to augment the global antimania drugs market growth over the forecast period. For instance, in July 2018, Lumateperone received positive results from the Phase 3 clinical trial (Study 401 and Study 404) for the treatment of bipolar depression, announced by Intra-Cellular Therapies, Inc. In both the trials (Study 401 and Study 404), Lumateperone was found safer and tolerable by patients.
Moreover, in October 2019, Psychiatry Consortium, which is a strategic collaboration of leading medical research charities and pharmaceutical companies to promote innovative drug discovery in psychiatric diseases, had announced to introduce a novel drug project to address people with mental health conditions such as bipolar disorder, depression and other mental disorders.
Psychiatry Consortium is a pioneering collaboration between the pharmaceutical companies, healthcare companies as well as leading medical charities. Therefore, increasing such initiatives by companies to support the novel drug project, is again expected to increase the launch of new drugs for treatment of patients with mental health condition such as bipolar disorder and hence drives the global antimania drugs market growth.
Ask for PDF Brochure @
However, side effects associated with lithium for the treatment of bipolar disorder is expected to hinder the global antimania drugs market growth. For instance, if patient takes overdose of lithium, it causes anorexia. Additionally, prolong use of lithium can damage body’s ability to respond properly to the hormone vasopressin and can result into diabetes insipidus.
North America is expected to hold the largest market share in global antimania drugs market, due to increasing technological advancements such as BiAffect app by University of Illinois, Chicago that helps to facilitate accurate detection of a patient’s mood and mental state. For instance, in 2018, the University of Illinois, Chicago (UIC) launched BiAffect app, which helps to track manic disorder and depressive mood in the patient with biopolar disorder. Moreover, BiAffect app predict mood episodes by analyzing the stroke dynamics such as error and typing speed of the patient.
Moreover, growing approvals of drug such as Vraylar by U.S Food and Drug administration (FDA) for the treatment of bipolar disorder is another key factor that is expected to boost global antimania drugs market growth. For instance, in May 2019, Allergan plc and Gedeon Richter Plc announced to receive the approval from the U.S Food Drug Administration for expanded use of Vraylar (cariprazine) in the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
Eli Lilly and Company, Sumitomo Dainippon Pharma Co., Ltd, Allergan plc, Xian Janssen Pharmaceutical Ltd, Pfizer Inc., Otsuka Pharmaceutical, Taro Pharmaceutical Industries Ltd, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Torrent Pharmaceutical Ltd.
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Antimania Drugs Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Antimania Drugs Industry Impact
Chapter 2 Global Antimania Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Antimania Drugs (Volume and Value) by Type
2.3 Global Antimania Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Antimania Drugs Sales, Consumption, Export, Import by Regions
Chapter 5 North America Antimania Drugs Market Analysis
Chapter 6 East Asia Antimania Drugs Market Analysis
Chapter 7 Europe Antimania Drugs Market Analysis
Chapter 8 South Asia Antimania Drugs Market Analysis
Chapter 9 Southeast Asia Antimania Drugs Market Analysis
Chapter 10 Middle East Antimania Drugs Market Analysis
Chapter 11 Africa Antimania Drugs Market Analysis
Chapter 12 Oceania Antimania Drugs Market Analysis
Chapter 13 South America Antimania Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Antimania Drugs Business
Chapter 15 Global Antimania Drugs Market Forecast (2021-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027